Skip to main content

Table 2 Retention rates as of December 2020 and reasons for discontinuation for patients inducted on buprenorphine-naloxone therapy (n = 277)

From: Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.

  Number (%)
Overall 277
Continued treatment as of December 2020 190 (68.6)
90-day retention 223 (84.5)
180-day retention 192 (79.0)
In-person inductees 166
90-day retention 156 (93.9)
180-day retention 151 (91.5)
365-day retention 110 (79.1)
Telehealth inductees 111
90-day retention 67 (68.4)
180-day retention 40 (51.9)
Overall discontinued patients 87 (31.4)
Reason unknown 53 (19.1)
Transferred MAT care elsewhere 23 (8.3)
Deceased 5 (1.8)